Data / Drug companies / Catalent Indiana, LLC
Catalent Indiana, LLC: 29 products in the FDA NDC directory, labeler code 61434
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Catalent Indiana, LLC (labeler code 61434) lists 29 products in the FDA National Drug Code Directory. By type: 19 prescription drugs, 9 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on January 1, 2025.
The request: Watch Catalent Indiana, LLC (FDA labeler code 61434): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61434
- Products in commercial distribution
- 29
- Packages
- 31
- Finished drugs by generic name
- 0
- Prescription products
- 19
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 8
- Earliest marketing start
- October 16, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 25 | 86.2% |
| Export only | 3 | 10.3% |
| Bulk ingredients | 1 | 3.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 19 | 65.5% |
| Drugs for further processing | 9 | 31% |
| Bulk ingredients | 1 | 3.4% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 19 | 65.5% |
| Injection | 7 | 24.1% |
| Injection, powder, lyophilized, for solution | 2 | 6.9% |
| Solution | 1 | 3.4% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Aflibercept | 61434-077 | Injection, solution | Export only | January 1, 2025 |
| Ravulizumab | 61434-076 | Injection, solution | Drugs for further processing | January 1, 2025 |
| Nivolumab | 61434-075 | Injection, solution | Drugs for further processing | January 1, 2025 |
| Aflibercept | 61434-074 | Injection, solution | Drugs for further processing | January 1, 2025 |
| Aflibercept | 61434-073 | Injection, solution | Drugs for further processing | January 1, 2025 |
| Odronextamab | 61434-072 | Injection, solution | Export only | January 1, 2025 |
| Odronextamab | 61434-064 | Injection, solution | Export only | January 1, 2025 |
| Adalimumab | 61434-020 | Injection, solution | Drugs for further processing | January 1, 2025 |
| Semaglutide | 61434-068 | Injection, solution | Drugs for further processing | July 22, 2024 |
| Semaglutide | 61434-067 | Injection, solution | Drugs for further processing | July 22, 2024 |
| Imetelstat sodium | 61434-069 | Injection, powder, lyophilized, for solution | Drugs for further processing | June 24, 2024 |
| Benralizumab | 61434-066 | Injection, solution | Drugs for further processing | June 3, 2024 |
| Pozelimab | 61434-063 | Injection, solution | Drugs for further processing | August 18, 2023 |
| Aflibercept | 61434-062 | Injection, solution | Drugs for further processing | August 18, 2023 |
| Ansuvimab-zykl | 61434-071 | Injection, powder, lyophilized, for solution | Drugs for further processing | December 21, 2020 |
| Ansuvimab-zykl | 61434-070 | Injection | Drugs for further processing | December 21, 2020 |
| Atoltivimab, maftivimab, and odesivimab | 61434-052 | Injection, solution | Drugs for further processing | October 14, 2020 |
| Aflibercept | 61434-007 | Injection, solution | Drugs for further processing | August 12, 2019 |
| Cemiplimab | 61434-021 | Injection | Drugs for further processing | September 28, 2018 |
| Lanadelumab-flyo | 61434-019 | Injection, solution | Drugs for further processing | August 24, 2018 |
| Epinephrine | 61434-041 | Injection | Drugs for further processing | August 22, 2018 |
| Epinephrine | 61434-040 | Injection | Drugs for further processing | August 22, 2018 |
| Diluent | 61434-011 | Solution | Drugs for further processing | October 6, 2017 |
| Durvalumab | 61434-038 | Injection, solution | Drugs for further processing | May 1, 2017 |
| Durvalumab injection, solution | 61434-002 | Injection, solution | Drugs for further processing | May 1, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.